Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 May;14(5):682-689.
doi: 10.1513/AnnalsATS.201608-655OC.

Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension

Rahul G Argula  1 , Abhijit Karwa  2 , Abigail Lauer  3 , David Gregg  4 , Richard M Silver  5 , Carol Feghali-Bostwick  5 , Lynn M Schanpp  1 , Kim Egbert  1 , Bruce W Usher  4 , Viswanathan Ramakrishnan  3 , Paul M Hassoun  6 , Charlie Strange  1
Affiliations
Comparative Study

Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension

Rahul G Argula et al. Ann Am Thorac Soc. 2017 May.

Abstract

Rationale: Patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) continue to have an unacceptably high mortality rate despite the progress achieved with pulmonary arterial vasodilator therapies.

Objectives: We sought to determine whether SSc-PAH is a clinically distinct pulmonary vascular disease phenotype when compared with idiopathic pulmonary arterial hypertension (IPAH) on the basis of progression of echocardiographic right ventricular (RV) dysfunction.

Methods: Retrospective analysis of echocardiographic data in 13 patients with SSc-PAH and 11 patients with IPAH was used to delineate the progression of RV dysfunction during single or combination pulmonary arterial vasodilator therapy. All patients had right heart catheterization-confirmed pulmonary arterial hypertension as well as complete baseline (at the time of diagnosis) and follow-up (most recent) echocardiograms. We excluded patients with significant scleroderma-associated interstitial lung disease. Adjusting for time of follow-up and disease duration, we performed mixed model regression analyses comparing the changes between the two groups for different echocardiographic variables: tricuspid annular plane systolic excursion, tricuspid regurgitation jet velocity, right atrial area, and RV diameter.

Results: The mean ages for the SSc-PAH and IPAH groups were 60.8 and 48.2 years, respectively. The mean follow-up periods for the two groups were 3.8 and 1.95 years, respectively. Tricuspid annular plane systolic excursion did not improve in patients with SSc-PAH, whereas it increased in the patients with IPAH (-0.38 mm, P = 0.87; vs. +5.6 mm, P = 0.02). The other echocardiographic variables showed a trend toward worsening in the SSc-PAH group and improvement in the IPAH group.

Conclusions: Our results indicate that, in patients with SSc-PAH, echocardiographic RV function does not improve over time compared with that of patients with IPAH, despite institution of pulmonary artery vasodilator therapies.

Keywords: disease progression; idiopathic pulmonary arterial hypertension; pulmonary arterial hypertension; right ventricle; systemic sclerosis–associated pulmonary arterial hypertension.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Disease duration and follow-up time. Right heart catheterization (RHC) was used to diagnose pulmonary arterial hypertension. Baseline ECHO = first available echocardiogram; follow-up ECHO = most recent echocardiogram.
Figure 2.
Figure 2.
Consolidated Standards of Reporting Trials (CONSORT) diagram showing the selection of patients with systemic sclerosis–associated pulmonary arterial hypertension (SSc-PAH) and patients with idiopathic pulmonary arterial hypertension (IPAH) for this study. PAH = pulmonary arterial hypertension; PH = pulmonary hypertension; UCTD = undifferentiated connective tissue disease; WHO = World Health Organization.
Figure 3.
Figure 3.
Change in mean tricuspid annular plane systolic excursion (TAPSE) from baseline to follow-up. The error bars represent the SEM. IPAH = idiopathic pulmonary arterial hypertension; SSc-PAH = systemic sclerosis-associated pulmonary arterial hypertension.
See this image and copyright information in PMC

References

    1. Condliffe R, Howard LS. Connective tissue disease-associated pulmonary arterial hypertension. F1000Prime Rep. 2015;7:06. - PMC - PubMed
    1. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, et al. Connective tissue disease–associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179:151–157. - PubMed
    1. Lefèvre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, Hatron PY, Humbert M, Launay D. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65:2412–2423. - PubMed
    1. Rubenfire M, Huffman MD, Krishnan S, Seibold JR, Schiopu E, McLaughlin VV. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. Chest. 2013;144:1282–1290. - PubMed
    1. Muangchan C, Canadian Scleroderma Research Group, Markland J, Robinson D, Jones N, Khalidi N, Docherty P, Kaminska E, Masetto A, Sutton E, et al. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review J Rheumatol 2013401545–1556. - PubMed

Publication types

MeSH terms